Early Post-Marketing Study of Eliquis (Apixaban), in Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE in Adults
Phase of Trial: Phase IV
Latest Information Update: 01 Jul 2017
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 27 Jun 2017 Status changed from recruiting to completed.
- 06 Jan 2016 Planned End Date changed from 1 Feb 2017 to 1 May 2017 as reported by ClinicalTrials.gov.
- 06 Jan 2016 Planned primary completion date changed from 1 Feb 2017 to 1 May 2017 as reported by ClinicalTrials.gov.